Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF)

References

• American Thoracic Society/European Respiratory Society International. Multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002, 165, 277–304.
   PubMedGoogle Scholar
• American Thoracic Society (ATS) and the European Respiratory Society (ERS). Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000, 161, 646–664.
   PubMed Web of Science ®Google Scholar
• Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 157, 199–203.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, Martinez FJ. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001, 164, 1722–1727.
   PubMed Web of Science ®Google Scholar
• Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000, 162, 2213–2217.
   PubMed Web of Science ®Google Scholar
• Carrington CB, Gaensler EA, Coutu RE, FitzGerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978, 298, 801–809.
   PubMed Web of Science ®Google Scholar
• Stack BH, Choo-Kang YF, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972, 27, 535–542.
   PubMed Web of Science ®Google Scholar
• Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980, 35, 496–499.
   PubMed Web of Science ®Google Scholar
• Matsushita H, Tanaka S, Saiki Y, Hara M, Nakata K, Tanimura S, Banba J. Lung cancer associated with usual interstitial pneumonia. Pathol Int 1995, 45, 925–932.
   PubMed Web of Science ®Google Scholar
• Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000, 161, 5–8.
   PubMed Web of Science ®Google Scholar
• Mizushima Y, Kobayashi M. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest 1995, 108, 1272–1277.
   PubMed Web of Science ®Google Scholar
• Takeuchi E, Yamaguchi T, Mori M, Tanaka S, Nakagawa M, Yokota  S, Nishikawa H, Noma K, Itoh M, Ogura T. Characteristics and management of patients with lung cancer and idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 1996, 34, 653–658.
   PubMedGoogle Scholar
• West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3′-kinase/Akt pathway in vitro and in vivo. Cancer Res 2004, 64, 446–451.
   PubMed Web of Science ®Google Scholar
• Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 2004, 91, 169–200.
   PubMed Web of Science ®Google Scholar
• Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers–a different disease. Nat Rev Cancer 2007, 7, 778–790.
   PubMed Web of Science ®Google Scholar
• Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007, 2, 327–343.
   PubMed Web of Science ®Google Scholar
• Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba II. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005, 65, 7568–7572.
   PubMed Web of Science ®Google Scholar
• Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung  MC. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13, 385–393.
   PubMed Web of Science ®Google Scholar
• Hengartner MO. The biochemistry of apoptosis. Nature 2000, 407, 685–7.
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Soufla G, Lymbouridou R, Economidou F, Lasithiotaki I, Manousakis M, Drositis I, Spandidos DA, Siafakas  NM. Expression analysis of angiogenic growth factors and biological axis CXCL12/CXCR4 axis in idiopathic pulmonary fibrosis. Connect Tissue Res 2010, 51, 71–80.
   PubMed Web of Science ®Google Scholar
• Lymbouridou R, Soufla G, Chatzinikola AM, Vakis A, Spandidos  DA. Down-regulation of K-ras and H-ras in human brain gliomas. Eur J Cancer 2009, 45, 1294–1303.
   PubMed Web of Science ®Google Scholar
• Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 2004, 91 (Suppl 2), S3–10.
   Google Scholar
• Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010, 35, 496–504.
   PubMed Web of Science ®Google Scholar
• Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker  M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales  L, Politi KA, Perera S, Getlik M, Heukamp LC, Ansén  S, Zander T, Beroukhim R, Kashkar H, Shokat KM, Sellers WR, Rauh  D, Orr C, Hoeflich KP, Friedman L, Wong KK, Pao W, Thomas RK. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 2009, 106, 18351–18356.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay  R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría  C, Weissleder R, Mahmood U, Cantley LC, Wong KK. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14, 1351–1356.
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006, 3, 350–356.
   PubMedGoogle Scholar
• Horowitz JC, Lee DY, Waghray M, Keshamouni VG, Thomas PE, Zhang H, Cui Z, Thannickal VJ. Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem 2004, 279, 1359–1367.
   PubMed Web of Science ®Google Scholar
• Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006, 51, 181–191.
   PubMed Web of Science ®Google Scholar
• Symvoulakis EK, Zaravinos A, Panutsopulos D, Zoras O, Papalambros E, Sigala F, Spandidos DA. Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. Int J Biol Markers 2007, 22, 12–18.
   PubMed Web of Science ®Google Scholar
• Saxena N, Lahiri SS, Hambarde S, Tripathi RP. RAS: target for cancer therapy. Cancer Invest 2008, 26, 948–955.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Munakata M, Ohtsuka Y, Nisihara H, Nasuhara Y, Kamachi-Satoh A, Dosaka-Akita H, Homma Y, Kawakami Y. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis. Cancer 2002, 95, 624–633.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague  J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks  E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt  S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper  C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949–954.
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, Nicholson AG, du Bois RM, Wells AU. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med 2008, 177, 190–194.
   PubMed Web of Science ®Google Scholar
• Demopoulos K, Arvanitis DA, Vassilakis DA, Siafakas NM, Spandidos DA. MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. J Cell Mol Med 2002, 6, 215–222.
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Papadaki HA, Soufla G, Siafakas NM. Short telomeres and treatment of pulmonary fibrosis: implications for early intervention. Am J Respir Crit Care Med 2009, 179, 970.
   PubMed Web of Science ®Google Scholar
• Boldrini L, Alì G, Gisfredi S, Ursino S, Baldini E, Melfi F, Lucchi M, Comin CE, Maddau C, Tibaldi C, Camacci T, Servadio A, Mussi A, Fontanini G. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. Oncol Rep 2009, 22, 683–691.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Miller MA, Bejarano PA, Heffelfinger  SC. Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 1999, 16, 57–61.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper  AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114, 1308–1316.
   PubMed Web of Science ®Google Scholar
• Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J Pharmacol Exp Ther 2007, 321, 35–44.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR. Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010, 181, 604–610.
   PubMed Web of Science ®Google Scholar
• Vargaftig BB, Singer M. Leukotrienes mediate part of Ova-induced lung effects in mice via EGFR. Am J Physiol Lung Cell Mol Physiol 2003, 285, L808–L818.
   Google Scholar
• Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007, 353, 104–108.
   PubMed Web of Science ®Google Scholar
• Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, Hagood JS. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008, 39, 610–618.
   PubMed Web of Science ®Google Scholar
• Wojdacz TK, Hansen LL. Techniques used in studies of age-related DNA methylation changes. Ann N Y Acad Sci 2006, 1067, 479–487.
   PubMed Web of Science ®Google Scholar